Ad
related to: depo-provera contraindications"Shop around for the best prices without a membership fee." - Today
- GoodRx® Press
"Shop wisely with GoodRx"
Featured on CNN & Forbes.
- Research You Can Rely On
Our team works hard to provide you
with the latest healthcare info.
- GoodRx® & Medicare
Beat your Medicare Copay!
Discover More Savings Options Today
- Our Social Impact Mission
At GoodRx, values matter. Visit us
to see how we make a difference.
- GoodRx® Press
Search results
Results from the WOW.Com Content Network
DMPA, under brand names such as Depo-Provera and Depo-SubQ Provera 104, is used in hormonal birth control as a long-lasting progestogen-only injectable contraceptive to prevent pregnancy in women. [ 38 ] [ 39 ] It is given by intramuscular or subcutaneous injection and forms a long-lasting depot , from which it is slowly released over a period ...
Medroxyprogesterone acetate (brand names Depo-Provera, Provera, Depo-subQ Provera 104) [4] – 150 mg (intramuscularly) or 104 mg (subcutaneously) every 3 months [3] Norethisterone enanthate (brand names NET EN, Noristerat, Norigest, Doryxas) [ 5 ] – 200 mg (intramuscularly) every 2 months [ 3 ]
The first progestogen-only contraceptive was introduced in 1969: Depo-Provera, a high-dose progestin injection. [54] Over the next decade and a half, other types of progestogen-only contraceptive were developed: a low-dose progestogen only pill (1973); [ 55 ] Progestasert, the first hormonal intrauterine device (1976); [ 56 ] and Norplant , the ...
Depo-Estradiol: Estrogen: IM, SC: 2–10 mg/wk or 5–20 mg every 2 wks Estradiol dipropionate: Agofollin: Estrogen: IM, SC: 2–10 mg/wk or 5–20 mg every 2 wks Estradiol benzoate: Progynon-B: Estrogen: IM, SC: 0.5–1.5 mg every 2–3 days Estriol: Ovestin [c] Estrogen: Oral: 4–6 mg/day Spironolactone: Aldactone: Antiandrogen: Oral: 100 ...
Depot MPA (DMPA) and EC/MPA were developed by Upjohn in the 1960s. [12] [13] DMPA (brand name Depo-Provera) was introduced for use as a progestogen-only injectable contraceptive for the first time outside of the United States in 1969 and was subsequently approved for use in birth control in the United States in 1992.
As of November 17, 2004, the FDA has required a boxed warning on the Depo-Provera contraceptive injection, due to the risk of significant loss of bone density with long-term use. [ 8 ] In April 2005, FDA advisors requested that Pfizer place a boxed warning on their non-steroidal anti-inflammatory drug Celebrex ( celecoxib ) for cardiovascular ...
CICs are different from progestogen-only injectable contraceptives (POICs), such as depot medroxyprogesterone acetate (DMPA; brand names Depo-Provera, Depo-SubQ Provera 104) and norethisterone enantate (NETE; brand name Noristerat), which are not combined with an estrogen and are given once every two to three months instead of once a month. [2]
Medroxyprogesterone, also known as 6α-methyl-17α-hydroxyprogesterone or as 6α-methyl-17α-hydroxypregn-4-en-3,20-dione, is a synthetic pregnane steroid and a derivative of progesterone.